Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 23, 2015 - Issue sup1
Submit an article Journal homepage
862
Views
36
CrossRef citations to date
0
Altmetric
Review of Ocular Behçet's Disease in Japan

A Major Review: Current Aspects of Ocular Behçet's Disease in Japan

Kenichi NambaDepartment of Ophthalmology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, Correspondence[email protected]
, MD, PhD,
Hiroshi GotoDepartment of Ophthalmology, Tokyo Medical University, Tokyo, Japan,
, MD, PhD,
Toshikatsu KaburakiDepartment of Ophthalmology, University of Tokyo Graduate School of Medicine, Tokyo, Japan,
, MD, PhD,
Nobuyoshi KitaichiDepartment of Ophthalmology, Health Sciences University of Hokkaido, Sapporo, Japan,
, MD, PhD,
Nobuhisa MizukiDepartment of Ophthalmology, Yokohama City University School of Medicine, Yokohama, Japan, and
, MD, PhD,
Yuri AsukataDepartment of Ophthalmology, Yokohama City University School of Medicine, Yokohama, Japan, and
, MD, PhD,
Yujiro FujinoDepartment of Ophthalmology, The Tokyo Kosei Nenkin Hospital, Tokyo, Japan
, MD, PhD,
Akira MeguroDepartment of Ophthalmology, Yokohama City University School of Medicine, Yokohama, Japan, and
, PhD,
Shunya SakamotoDepartment of Ophthalmology, Tokyo Medical University, Tokyo, Japan,
, MD,
Etsuko ShibuyaDepartment of Ophthalmology, Yokohama City University School of Medicine, Yokohama, Japan, and
, MD, PhD,
Katsutoshi YokoiDepartment of Ophthalmology, Tokyo Medical University, Tokyo, Japan,
, MD, PhD &
Shigeaki OhnoDepartment of Ophthalmology, Hokkaido University Graduate School of Medicine, Sapporo, Japan,
, MD, PhD show all
Pages S1-S23 | Received 05 Jan 2014, Accepted 22 Oct 2014, Published online: 13 Jul 2015

References

  • Goto H, Mochizuki M, Yamaki K, et al. Epidemological survey of intraocular inflammation in Japan. Jpn J Ophthalmol. 2007;51:41–44
  • Nishiyama M, Nakae K, Yukawa S, et al. A study of comparison between the nationwide epidemiological survey in 1991 and previous surveys on Behçet’s disease in Japan. Environ Health Prevent Med. 1999;4:130–134
  • de Menthon M, Lavalley MP, Maldini C, et al. HLA-B51/B5 and the risk of Behçet’s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61:1287–1296
  • Remmers EF, Cosan F, Kirino Y, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet’s disease. Nat Genet. 2010;42:698–702
  • Mizuki N, Meguro A, Ota M, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet’s disease susceptibility loci. Nat Genet. 2010;42:703–706
  • Kirino Y, Bertsias G, Ishigatsubo Y, et al. Genome-wide association analysis identifies new susceptibility loci for Behçet’s disease and epistasis between HLA-B*51 and ERAP1. Nat Genet. 2013;45:202–207

References

  • International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078–1080
  • Dervis E, Geyik N. Sensitivity and specificity of different diagnostic criteria for Behçet’s disease in a group of Turkish patients. J Dermatol. 2005;32:266–272
  • Inaba H. National immunological survey of Behçet’s disease: estimated number of patients. Report of research project supported by scientific research grant from the Ministry of Health, Labour, and Welfare (Intractable Disease Control Research Project): overall and individual group reports for research on Behçet’s disease (2004). 2005:89–90 [in Japanese]
  • Inaba H. National immunological survey of Behçet’s disease: clinical epidemiology. Report of research project supported by scientific research grant from the Ministry of Health, Labour, and Welfare (Intractable Disease Control Research Project): overall and individual group reports for research on Behçet’s disease (2004). 2005:91–94 [in Japanese]
  • Tugal-Tultkun I, Gupta V, Cunningham ET. Differential diagnosis of Behçet’s disease. Ocul Immunol Inflamm. 2013;21:337–350

References

  • Sakai JI, Usui Y, Sakai M, et al. Clinical statistics of endogenous uveitis: comparison between general eye clinic and university hospital. Int Ophthalmol. 2010;30:297–301
  • Mishima S, Masuda K, Izawa Y, et al. The eighth Frederick H. Verhoeff Lecture. Presented by Saiichi Mishima, MD, Behçet’s disease in Japan: ophthalmologic aspects. Trans Am Ophthalmol Soc. 1979;77:225–279
  • Suzuki Kurokawa M, Suzuki N. Behçet’s disease. Clin Exp Med. 2004;4:10–20
  • International Study Group for Behçet’s Disease: criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078–80
  • Hirohata S, Kikuchi H. Changes in biomarkers focused on differences in disease course or treatment in patients with neuro-Behçet’s disease. Intern Med. 2012;51:3359–3365
  • de Menthon M, Lavalley MP, Maldini C, et al. HLA-B51/B5 and the risk of Behçet’s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61:1287–1296
  • Remmers EF, Cosan F, Kirino Y, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet’s disease. Nat Genet. 2010;42:698–702
  • Meguro A, Inoko H, Ota M, et al. Genetics of Behçet disease inside and outside the MHC. Ann Rheum Dis. 2010;69:747–754
  • Davies PG, Fordham JN, Kirwan JR, et al. The pathergy test and Behçet’s syndrome in Britain. Ann Rheum Dis. 1984;43:70–73
  • Friedman-Birnbaun R, Bergman R, Aizen, E. Sensitivity and specificity of pathergy test results in Israeli patients with Behçet’s disease. Cutis. 1990;45:261–264
  • Davachi F, Chans-Davachi C, Shahram F, et al. Pathergy test in Behçet’s disease in incidence over the time. APKAR J Rheumatol. 2007;10:333–335
  • Togashi A, Saito S, Kaneko F, et al. Skin prick test with self-saliva in patients with oral aphthoses: a diagnostic pathergy for Behçet’s disease and recurrent aphthosis. Inflamm Allergy Drug Targets. 2011;10:164–170
  • Chang HK, Cheon KS. The clinical significance of a pathergy reaction in patients with Behçet’s disease. J Korean Med Sci. 2002;17:371–374
  • The Behçet’s Disease Research Committee of Japan. Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Behçet’s disease—a multicenter study. J Rheumatol. 1989;16:506–511
  • Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160:736–55
  • Asukata Y, Ishihara M, Hasumi Y, et al. Guidelines for the diagnosis of ocular sarcoidosis. Ocul Immunol Inflamm. 2008;16:77–81
  • Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516
  • Parchand S, Tandan M, Gupta V, Gupta A. Intermediate uveitis in Indian population. J Ophthal Inflamm Infect. 2011;1:65–70

References

  • Matsumura N, Mizushima Y. Leucocyte movement and colchicine treatment in Behçet’s disease. Lancet. 1975;2:813
  • Kotter I, Durk H, Saal J, et al. Therapy of Behçet’s disease. Ger J Ophthalmol. 1996;5:92–97
  • Aktulga E, Altaç M, Müftüoglu A, et al. A double blind study of colchicine in Behçet’s disease. Haematologica. 1980;65:399–402
  • Nussenblatt RB, Palestine AG, Chan CC, et al. Effectiveness of cyclosporin therapy for Behçet’s disease. Arthritis Rheum. 1985;28:671–679
  • Süllü Y, Oge I, Erkan D, et al. Cyclosporin—a therapy in severe uveitis of Behçet’s disease. Acta Ophthalmol Scand. 1998;76:96–99
  • Ozdal PC, Ortaç S, Taskintuna I, Firat E. Long-term therapy with low-dose cyclosporin A in ocular Behçet’s disease. Doc Ophthalmol. 2002;105:301–312
  • Nussenblatt RB, Palestine AG. Cyclosporine: immunology, pharmacology and therapeutic uses. Surv Ophthalmol. 1986;31:159–169
  • Kotake S, Higashi K, Yoshikawa K, et al. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology. 1999;106:586–589
  • Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362–1368
  • Okada AA, Goto H, Ohno S, Mochizuki M; Ocular Behçet’s Disease Research Group of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol. 2012;130:592–598
  • Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease: an open-label trial. Arthritis Rheum. 2005;52:2478–2484
  • Al-Rayes H, Al-Swailem R, Al-Balawi M, et al. Safety and efficacy of infliximab therapy in active behçet’s uveitis: an open-label trial. Rheumatol Int. 2008;29:53–57
  • Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. Am J Ophthalmol. 2008;146:845–850
  • Yamada Y, Sugita S, Tanaka H, et al. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Br J Ophthalmol. 2010;94:284–288
  • Keino H, Watanabe T, Taki W, Okada AA. Effect of infliximab on gene expression profiling in Behçet’s disease. Invest Ophthalmol Vis Sci. 2011;52:7681–7686
  • Iwata D, Namba K, Mizuuchi K, et al. Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet’s disease with infliximab. Graefes Arch Clin Exp Ophthalmol. 2012;250:1081–1087
  • Takeuchi M, Asukata Y, Kawagoe T, et al. Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behçet’s disease. Ocul Immunol Inflamm. 2012;20:193–197
  • Capella MJ, Foster CS. Long-term efficacy and safety of infliximab in the treatment of Behçet’s disease. Ocul Immunol Inflamm. 2012;20:198–202
  • Yoshida A, Kaburaki T, Okinaga K, et al. Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy. Jpn J Ophthalmol. 2012;56:536–543
  • Sakai T, Watanabe H, Kuroyanagi K, et al. Health- and vision-related quality of life in patients receiving infliximab therapy for Behçet uveitis. Br J Ophthalmol. 2013;97:338–342
  • Kikuchi H, Aramaki K, Hirohata S. Effect of infliximab in progressive neuro-Behçet’s syndrome. J Neurol Sci. 2008;272:99–105
  • Iwata S, Saito K, Yamaoka K, et al. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behçet’s disease. Rheumatology. 2009;48:1012–1013
  • Kasugai C, Watanabe D, Mizutani K, et al. Infliximab treatment of severe genital ulcers associated with Behçet disease. J Am Acad Dermatol. 2010;62:162–164
  • Rokutanda R, Okada M, Yamaguchi K, et al. Infliximab for Behçet disease with aortic involvement: two novel case reports without concurrent use of immunosuppressive agents or corticosteroids. Mod Rheumatol. 2013;23:412–413
  • Lee JH, Cheon JH, Jeon SW, et al. Efficacy of infliximab in intestinal Behçet’s disease: a Korean multicenter retrospective study. Inflamm Bowel Dis. 2013;19:1833–1838
  • Kinoshita H, Kunisaki R, Yamamoto H, et al. Efficacy of infliximab in patients with intestinal Behçet’s disease refractory to conventional medication. Intern Med. 2013;52:1855–1862
  • Li J, Fernando S, Herkes G. Use of infliximab and other biologics in Behçet disease. Intern Med J. 2014;44:96–100
  • Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med. 1990;322:281–285
  • Saadoun D, Wechsler B, Terrada C, et al. Azathioprine in severe uveitis of Behçet’s disease. Arthritis Care Res. 2010;62:1733–1738
  • Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87:423–431
  • Tugal-Tutkun I, Güney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol. 2006;244:1692–1695
  • Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007;91:335–339
  • Krause L, Altenburg A, Pleyer U, et al. Long-term visual prognosis of patients with ocular Adamantiades-Behçet’s disease treated with interferon-alpha-2a. J Rheumatol. 2008;35:896–903
  • Onal S, Kazokoglu H, Direskeneli H, Yavuz S. Low-dose interferon alfa-2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol. 2009;147:1109–1110
  • Sobaci G, Erdem U, Durukan AH, et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet’s uveitis refractory to conventional treatments. Ophthalmology. 2010;117:1430–1435
  • Deuter CM, Zierhut M, Möhle A, et al. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet’s disease. Arthritis Rheum. 2010;62:2796–2805
  • Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Arch Ophthalmol. 2011;129:288–294
  • Yalçindağ FN, Uzun A. Results of interferon alpha-2a therapy in patients with Behçet’s disease. J Ocul Pharmacol Ther. 2012;28:439–443
  • Namba K, Sonoda KH, Kitamei H, et al. Granulocytapheresis in patients with refractory ocular Behçet’s disease. J Clin Apher. 2006;21:121–128
  • Ohguro N, Yamanaka E, Otori Y, et al. Repeated intravitreal triamcinolone injections in Behçet disease that is resistant to conventional therapy: one-year results. Am J Ophthalmol. 2006;141:218–220
  • Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113:1020–1027

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.